| Title |
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
|
|---|---|
| Published in |
Clinical, Cosmetic and Investigational Dermatology, May 2024
|
| DOI | 10.2147/ccid.s464326 |
| Pubmed ID | |
| Authors |
Matteo Megna, Angelo Ruggiero, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2024.
All research outputs
#4,996,926
of 26,005,389 outputs
Outputs from Clinical, Cosmetic and Investigational Dermatology
#294
of 929 outputs
Outputs of similar age
#48,850
of 247,173 outputs
Outputs of similar age from Clinical, Cosmetic and Investigational Dermatology
#1
of 5 outputs
Altmetric has tracked 26,005,389 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 929 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them